Support the Institute


The visionary structure of the Institute, as well as the generous support of the Robert A. and Renee E. Belfer Foundation and the institute’s donors, enable the Belfer Institute to integrate its scientific teams, access cancer models and leverage a broad range of leading edge research capabilities, giving the Institute a direct line of sight from the cancer genome to patient treatment.

The following donors have generously supported the Belfer Institute for Applied Cancer Science by making gifts totaling $100,000 or more.


Aid for Cancer Research

The Arthur & Rochelle Belfer Foundation, Inc.

The Robert A. & Renée E. Belfer Family Foundation

Irene E. & George A. Davis Foundation

Mary E. Davis

Expect Miracles Foundation

Flight Attendant Medical Research Institute

Marion Huber Trust

The Estate of Lily I. Jutila

Geraldine C. & Bennett S. LeBow

Mutual Funds Against Cancer Golf Classic

The Smolokowski Family

denotes deceased individuals

In the News

Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".

read more >

Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.

read more >

Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.

read more >

Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer

read more >

Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer

read more >

Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.

read more >

Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.

read more >

Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.

read more >